Metabolic disorders, including obesity and insulin resistance, have their basis in dysregulated lipid metabolism and low-grade inflammation. In a microarray search of unique lipase-related genes whose expressions are associated with obesity, we found that two secreted phospholipase A 2 s (sPLA 2 s), PLA2G5 and PLA2G2E, were robustly induced in adipocytes of obese mice. Analyses of Pla2g5
INTRODUCTION
Type 2 diabetes and metabolic syndrome are increasing at an explosive rate worldwide due to a pandemic of obesity associated with insulin resistance, nonalcoholic fatty liver disease, and hyperlipidemia (Despré s and Lemieux, 2006) . The mechanisms connecting obesity to insulin resistance include an elevation of circulating lipids, ectopic lipid deposition leading to lipotoxicity, and chronic inflammation in metabolically active tissues (Hotamisligil, 2006) . Obesity relies on dysregulations of intracellular lipid metabolism or extracellular lipid partitioning among tissues, and perturbation of intracellular/extracellular lipases or related enzymes variably and often profoundly affect obesity and insulin resistance (Chen et al., 2008; Chiu et al., 2010; Haemmerle et al., 2006; Jaworski et al., 2009; Tian et al., 2010; Wang et al., 2011) .
Among the phospholipase A 2 (PLA 2 ) family, secreted PLA 2 s (sPLA 2 s) have been implicated in inflammation and atherosclerosis, since they can augment the production of proinflammatory lipid mediators and hydrolyze phospholipids in lipoproteins to generate proatherogenic particles in vitro (Murakami et al., 2011) . Recent genetic studies have revealed that individual sPLA 2 s, which show distinct tissue distributions and substrate preferences, participate in diverse biological events in response to given microenvironmental cues (Sato et al., 2010; Taketomi et al., 2013) . However, the regulatory roles of sPLA 2 s in metabolic disorders are not well understood. Except for studies using sPLA 2 -overexpressing transgenic mice (Ivandic et al., 1999; Sato et al., 2008) , no reports have firmly established whether sPLA 2 s could affect lipoprotein metabolism in vivo. Moreover, although sPLA 2 s exert anti-inflammatory effects in certain situations (Ait-Oufella et al., 2013; Miki et al., 2013) , except for PLA2G2D (group IID), a ''resolving sPLA 2 '' that ameliorates inflammation by mobilizing proresolving lipid mediators (Miki et al., 2013) , the molecular mechanisms for the anti-inflammatory actions of sPLA 2 s remain elusive.
In our efforts to search for particular lipase-related genes whose roles in obesity have not been addressed before, we found that two particular sPLA 2 s, PLA2G5 (group V) and PLA2G2E (group IIE), were robustly induced in adipose tissue of obese mice. Reportedly, PLA2G5 deficiency exacerbates or Cell Metabolism 20, 1-14, July 1, 2014 ª2014 Elsevier Inc. 1 attenuates inflammation according to disease contexts in unknown ways (Murakami et al., 2011) . Notably, PLA2G5 gene polymorphisms correlate with low-density lipoprotein (LDL) levels in subjects with type 2 diabetes or obesity (Sergouniotis et al., 2011; Wootton et al., 2007) , and in vitro PLA2G5 susceptibility of LDL from patients with type 2 diabetes is greater than that of LDL from healthy subjects (Pettersson et al., 2008) , suggesting a role of this sPLA 2 in metabolic regulation. After the identification of PLA2G2E (Suzuki et al., 2000; Valentin et al., 1999) , its expression, target phospholipids, and biological roles in vivo have remained a mystery for more than a decade. We now provide evidence that the two diet-inducible, adipocyte-driven ''metabolic sPLA 2 s'' play distinct roles in obesity, hyperlipidemia, and insulin resistance, thus highlighting the importance of the sPLA 2 family in lipoprotein hydrolysis and immune regulation in the process of metabolic disorders.
RESULTS

PLA2G5 and PLA2G2E Are Induced in Adipocytes of Obese Mice
We performed gene profiling by microarray followed by quantitative RT-PCR of perigonadal white adipose tissue (WAT) from C57BL/6 mice fed a high-fat diet (HFD; 60% fat calorie) in comparison with those maintained on a low-fat diet (LFD; 4.8% fat calorie) to identify particular lipase-related genes whose expression levels were altered by diets and whose functions in obesity are currently unknown. We found that Pla2g5 and Pla2g2e, two members of the sPLA 2 family, were highly induced in the WAT of HFD-fed mice compared with LFD-fed mice, ranking two of the top three among the diet-inducible lipase-related genes (Figure 1A; Table S1 , available online). Marked induction of these two sPLA 2 s, but not other sPLA 2 s ( Figure 1B ) and intracellular PLA 2 s ( Figure S1A ), in the WAT of HFD-fed mice was confirmed by quantitative PCR. As in mice, the expression of PLA2G5 was much higher than that of most other sPLA 2 s in human mesenteric WAT and fatty appendices, while that of PLA2G2E was very low ( Figure 1C ; Table S2 ). Note that PLA2G2A, which is highly homologous to PLA2G2E (Suzuki et al., 2000; Valentin et al., 1999) and absent in C57BL/6 mice due to a natural mutation (MacPhee et al., 1995) , was highly expressed in human WAT, suggesting that PLA2G2E in mice might be compensated by PLA2G2A in humans.
Among the tissues with high lipid demand, constitutive Pla2g5 expression in heart and skeletal muscle was unaffected by diet, and its expression in WAT of HFD-fed mice exceeded that in any other tissues examined so far and reached a level much higher than that in bone marrow (BM)-derived denditic cells (BMDCs) and macrophages (BMDMs) ( Figure 1D ). HFD-induced expression of Pla2g2e occurred robustly in WAT and brown adipose tissue (BAT), while its expression in other tissues and cells was low ( Figure 1E ). Moreover, WAT expression of both sPLA 2 s was far greater in genetically obese Lep ob/ob mice than in control mice ( Figure 1F ). Kinetic experiments after HFD feeding revealed robust induction of Pla2g5 and Pla2g2e in WAT by 8 weeks, thereafter reaching a maximal plateau level ( Figure S1A ). The kinetic induction of Pla2g5 and Pla2g2e was similar to that of Lep, which encodes leptin (Pelleymounter et al., 1995) , but differed from that of adipogenic or immune cell markers ( Figure S1A ).
More detailed kinetic studies at an earlier period showed that the HFD induction of Pla2g2e preceded that of Pla2g5 (Figure S1B ). When the WAT was separated into adipocytes and stromal vascular fraction (SVF), both sPLA 2 s were located predominantly in adipocytes of HFD-fed mice ( Figures 1G and S1C) .
Expression of Pla2g5 and Pla2g2e was increased markedly in mouse 3T3-L1 preadipocytes after culture for 14 days with an adipogenic cocktail ( Figure S1D ). Proinflammatory cytokines failed to affect their expression in 3T3-L1 cells ( Figure S1E ). Transwell culture of SVF cells and 3T3-L1 cells did not affect or even decreased the expression of Pla2g5 and Pla2g2e, while it increased that of Tnf and Ccl2, in the latter cells ( Figure S1F ), ruling out the contribution of SVF-derived soluble factors to the induction of these sPLA 2 s in adipocytes. Notably, Pla2g5, not Pla2g2e, expression in differentiated 3T3-L1 cells was further increased by the endoplasmic reticulum (ER) stress inducer thapsigargin ( Figure S1D ) or tunicamycin (data not shown). These results suggest that the inducible expression of Pla2g5 depends on the adipogenic program plus obesity-associated ER stress (Ozcan et al., 2006) , while adipogenesis is sufficient to drive Pla2g2e expression. During adipogenesis, Pla2g2e expression started to increase on day 3, lagging behind the induction of the adipogenic marker Pparg, and continued to increase by day 12 ( Figure S1G ).
Increased Diet-Induced Obesity in Pla2g5
-/-Mice To elucidate the role of PLA2G5 in obesity, we placed Pla2g5 -/-mice (Satake et al., 2004) and wild-type (WT) littermates on a HFD, along with a control group of each genotype on a LFD. HFD-induced obesity and weight gain were greater in Pla2g5 -/-mice than in Pla2g5 +/+ mice (Figures 2A and 2B ). Immunohistochemistry confirmed the location of PLA2G5 protein in adipocytes of HFD-fed WT mice, whereas hardly any such reactivity was seen in those of Pla2g5 -/-mice, which lacked Pla2g5 expression ( Figures S2A and S2B ). Computed tomography (CT) showed significant increases in total, visceral, and subcutaneous fat depositions in HFD-fed Pla2g5 -/-mice relative to Pla2g5 +/+ mice ( Figure 2C ). In agreement, the HFD-induced increase in plasma leptin, whose expression correlates with adiposity (Pelleymounter et al., 1995) , was higher in Pla2g5 -/-mice than in Pla2g5 +/+ mice ( Figure 2D ). Although daily food intake was the same for both groups, locomotion and oxygen consumption were lower in Pla2g5 -/-mice ( Figures S2C-S2E ), indicating decreased energy expenditure. The respiratory quotient was unchanged in Pla2g5 -/-mice ( Figure S2F ).
HFD-induced elevation of plasma insulin was greater in
Pla2g5
-/-mice than in Pla2g5 +/+ mice ( Figure 2E ), despite comparable hyperglycemia in both genotypes ( Figure S2G ), suggesting exacerbated insulin resistance in Pla2g5 -/-mice. Indeed, on an insulin tolerance test (ITT), HFD-fed Pla2g5 -/-mice had greater insulin resistance than Pla2g5 +/+ mice ( Figure 2F ). Insulin-stimulated Akt phosphorylation was lower in WAT, but not in skeletal muscle and liver, of Pla2g5 -/-mice than in that of Pla2g5 +/+ mice ( Figures 2G and S2H ), suggesting that Pla2g5 ablation decreases insulin sensitivity mainly in WAT, where PLA2G5 is induced. In a glucose tolerance test (GTT), the glucose disposal was similar in both genotypes ( Figure 2H ), probably because glucose-stimulated insulin secretion was greater in Pla2g5 -/-mice than in Pla2g5 +/+ mice ( Figure 2I ).
Exacerbated insulin resistance was already evident, whereas oxygen consumption was unaffected, in Pla2g5 À/À mice at 6 weeks after HFD feeding ( Figures S2I and S2J ), indicating that the metabolic dysfunction occurred prior to the decreased energy expenditure. HFD feeding led to greater adipocyte hypertrophy in WAT ( Figure 2J ) and BAT ( Figure S3A ) of Pla2g5 -/-mice compared to those of WT mice, although expression levels of adipogenic, lipogenic, lipid uptake, lipolytic, or thermogenic genes in WAT ( Figure 2K ) and BAT ( Figure S3B ) were similar between the genotypes. Expression of several other PLA 2 s, which have been implicated in adiposity (Su et al., 2004) , in WAT was unaffected by PLA2G5 deficiency ( Figure S3C ). Thus, the increased obesity in Pla2g5 -/-mice may not arise from intrinsic alterations in these adipocyte programs but may involve other extrinsic mechanisms. HFD-increased plasma alanine aminotransferase (ALT) level ( Figure 2L ) and hepatic fat deposition (Figures 2M and 2N) Figure 1D ), and since visceral adiposity and hepatic steatosis are etiologically intertwined (Despré s and Lemieux, 2006) , the abnormalities in these tissues may reflect a secondary effect resulting from the increased obesity in Pla2g5 -/-mice. 
(D and E) Levels of fasting plasma leptin (D) and insulin (E) in Pla2g5
+/+ and Pla2g5 -/-mice.
(F) ITT using 6 hr fasted Pla2g5 +/+ and Pla2g5 -/-mice.
(G) Immunoblotting of phosphorylated (P-) and total Akt in WAT of HFD-fed Pla2g5 +/+ and Pla2g5 -/-mice with (+) or without (À) 5 min treatment with insulin. The ratios of P-Akt to Akt were determined by densitometry, with the value of insulin-untreated Pla2g5 +/+ mice being regarded as 1 (n = 4).
(legend continued on next page)
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Metabolic sPLA 2 s in Obesity Altered Lipoprotein Profiles in HFD-Fed Pla2g5 -/-Mice PLA2G5 hydrolyzes phosphatidylcholine (PC) in LDL and, to a lesser extent, in high-density lipoprotein (HDL) in vitro (Sato et al., 2008 ), yet in vivo evidence for this action was lacking. Kinetically, HFD feeding was accompanied by increases of phospholipids in plasma and in lipoproteins ( Figure S4A ), which preceded Pla2g5 induction in WAT ( Figure S1A ). Plasma phospholipid and cholesterol levels were significantly greater in HFD-fed Pla2g5 -/-mice than in Pla2g5 +/+ mice ( Figure 3A ).
Moreover, phospholipid, cholesterol, and TG levels in LDL, but not chylomicron (CM), very-low-density lipoprotein (VLDL), and HDL, were significantly higher in HFD-fed Pla2g5 -/-mice than in Pla2g5 +/+ mice ( Figures 3B-3D , S4B, and S4C). These results suggest that diet-induced PLA2G5 acts on LDL phospholipids, eventually altering LDL lipid composition.
To explore the hydrolysis of LDL phospholipids by PLA2G5 further, phospholipids in LDL from HFD-fed mice were analyzed by electrospray ionization mass spectrometry (ESI-MS S4D ). By contrast, PLA2G5 deficiency did not affect minor LDL phospholipids, phosphatidylethanolamine (PE), and phosphatidylserine (PS) ( Figure 3E ). These results imply that PLA2G5 preferentially hydrolyzes PC species (particularly those containing a fatty acid with a lower degree of unsaturation, such as OA in preference to LA [OA > LA]) in hyperlipidemic LDL in vivo, a view that agrees with its substrate preference in vitro (Pruzanski et al., 2005; Sato et al., 2008) . Plasma levels of nonesterified fatty acids (NEFA) and lysophosphatidylcholine (LPC), which are PLA 2 reaction products, did not differ in both genotypes ( Figure S4E ), probably because the PLA2G5-driven NEFA and LPC pools were small relative to their high background levels or because they were produced locally in WAT.
In support of the latter idea, the WAT level of OA was elevated in Pla2g5 +/+ mice after HFD feeding, whereas this increase was not seen in Pla2g5 À/À mice ( Figure 3F ). PUFAs (LA > AA > DHA) also tended to be lower in HFD-fed Pla2g5 À/À mice than in Pla2g5 +/+ mice, though to a lesser extent than OA. Overall, these lipid profiles agree with the fatty acid preference of PLA2G5. Thus, diet-induced PLA2G5 hydrolyzes PC in fat-overladen LDL to provide OA in preference to PUFAs in WAT, which may eventually contribute to LDL lipid normalization. Notably, as in mice, WAT expression levels of PLA2G5 showed a significantly inverse correlation with plasma LDL levels in humans ( Figure 3G ; Table S2 ), revealing an enzyme-substrate relationship across species.
Exacerbated Adipose Tissue Inflammation in HFD-Fed
Crown-like structures, an indication of macrophage infiltration, were histologically greater in the WAT of HFD-fed Pla2g5
-/-than in that of Pla2g5 +/+ mice ( Figure 2J ). Consistently, HFDinduced WAT expression of M1 macrophage markers was increased, whereas M2 macrophage markers were unchanged or decreased, by Pla2g5 deficiency, allowing the M1/M2 ratio to be greater in HFD-fed Pla2g5 -/-mice ( Figures 4A and 4B ). 4D ). Thus, PLA2G5 plays an anti-inflammatory role in adipose tissue inflammation. Recruitment of macrophages into obese WAT relies on several mechanisms, among which adipocyte death due to lipotoxicity represents a driving factor, attracting macrophages for phagocytic clearance of dead cells (Cinti et al., 2005) . As Pla2g5 -/-mice display lower macrophage phagocytosis (Balestrieri et al., 2009; Boilard et al., 2010) 
PLA2G5 Integrates Lipoprotein Metabolism and AntiInflammation
Given that sPLA 2 acts in a paracrine fashion, we speculated that PLA2G5 secreted from adipocytes affected the properties of macrophages. Addition of PLA2G5 to lipopolysaccharide and interferon g (LPS+IFN-g)-stimulated BMDMs augmented the expression of the M2 marker Arg1 without affecting that of the M1 marker Nos2 ( Figure 5A ), suggesting that PLA2G5 selectively upregulates the M2 gene. In a setting physiologically more relevant to sterile inflammation in obesity, exposure of BMDMs to PA, a saturated fatty acid that elicits proinflammatory responses through Toll-like receptor 4 (TLR4) or ER stress (Hotamisligil, 2006) , increased Nos2, did not affect Arg1, and decreased Cd206, indicative of M1 skewing ( Figures 5B and 5C ). Further addition of PLA2G5 to PA-treated BMDMs reduced Nos2, upregulated Arg1, and partially restored Cd206 expression (Figure 5B ). Pla2g5 expression was increased in PA-treated BMDMs ( Figure 5D ), in line with its induction by ER stress in adipocytes ( Figure S1D ). However, culture of Pla2g5 +/+ and Pla2g5 BMDMs under M1 or M2 skewing conditions led to a similar induction of respective macrophage subset markers ( Figure S5A ), suggesting that although PLA2G5 expressed at a low level in macrophages is insufficient to affect their polarization, it can facilitate the conversion of M1 to M2 macrophages when supplied abundantly through a paracrine route. Indeed, when irradiated WT mice were adoptively transferred with Pla2g5 -/-or Pla2g5 +/+ BM cells, HFD-induced obesity, insulin resistance, and hyperlipidemia were comparable in both groups ( Figures  S5B-S5D ). Thus, PLA2G5 in nonhematopoietic cells (likely adipocytes) appears to be mainly responsible for the amelioration of metabolic disorders. Of the potential PLA2G5-driven lipid mediators tested, prostaglandin E 2 (PGE 2 ), an AA metabolite, had the ability to induce Arg1, without affecting Nos2, in BMDMs stimulated with LPS+IFN-g ( Figure 5E ) or PA ( Figure 5F ). Exogenous PLA2G5 augmented PGE 2 generation by PA-stimulated BMDMs (Figure 5G) . In vivo, however, the WAT level of PGE 2 did not differ between HFD-fed Pla2g5 -/-and Pla2g5 +/+ mice, while that of PGD 2 was higher in the null mice, likely due to upregulation of PGD 2 synthase ( Figures S5E and S5F) . Thus, it is more likely that PLA2G5 action involves an alternative lipid-mediated process.
Proinflammatory ER stress induced by saturated fatty acids can be ameliorated by unsaturated fatty acids (Hotamisligil, 2006) . As PLA2G5 released OA > LA from LDL-PC ( Figures 3D  and 3E ), we examined whether these unsaturated fatty acids affected PA-induced M1 macrophage polarization. Strikingly, OA or LA canceled out the induction of Nos2 even at 2 mM and also restored the expression of Cd206 dose dependently in PA-treated BMDMs ( Figure 5H ). The WAT level of the PLA2G5-sensitive OA pool was within a range enough to affect macrophage polarization (Figures 3E and 5H) . Thus, OA, and possibly 
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PUFAs mobilized by PLA2G5 from LDL, may allow the polarization from M1 to M2 macrophages by attenuating the PA-induced stress response, which underscores a mechanistic link between PLA2G5-driven LDL hydrolysis and anti-inflammation in WAT.
PLA2G5 Is a Th2/M2-Prone sPLA 2 While T helper 2 (Th2) cytokines are proallergic, they facilitate M2 macrophage polarization, thereby counteracting adipose tissue inflammation and insulin resistance (Odegaard and Chawla, 2013) . It has been shown that PLA2G5 from both hematopoietic and nonhematopoietic origins regulates the Th2 response and thereby asthma (Giannattasio et al., 2010; Henderson et al., 2013) . Indeed, when WT mice were immunized intraperitoneally with ovalbumin (OVA), lymph node cells from Pla2g5 -/-mice expressed levels of IL-4 and IL-13 lower than those from Pla2g5 +/+ mice upon OVA challenge ex vivo ( Figure S5G ). Serum levels of total or OVA-specific immunoglobulin E (IgE) were lower in Pla2g5 -/-mice than in Pla2g5 +/+ mice ( Figure S5H ). Moreover, beyond the crucial role of adipocyte-rather than macrophagederived PLA2G5 in obesity, Pla2g5 expression in BMDMs was markedly induced by M2-skewing Th2 cytokines (IL-4 and IL-13) and was unaffected or reduced by M1-skewing TLR agonists (LPS and zymozan) or Th1 cytokines (IFN-g and granulocytemacrophage colony-stimulating factor [GM-CSF]) among others ( Figures S5I and S5J ). In ex vivo skewing culture of splenic naive CD4 + T cells, Pla2g5 was induced preferentially in IL-4-driven Th2 cells ( Figure S5K ). In the context of obesity, the WAT expression of Il33, a stromal Th2 cytokine that increases M2 macrophages and suppresses adipose tissue inflammation (Miller et al., 2010) , was lower in HFD-fed Pla2g5 -/-mice than in replicate Pla2g5 +/+ mice ( Figure 5I ). Thus, PLA2G5 is a unique sPLA 2 that is induced by Th2 cytokines and facilitates the Th2 and M2 responses. Pla2g5 À/À mice are Th2/M2 insufficient, and this intrinsic immune balance shift may also underlie the exacerbated adipose tissue inflammation.
Reduced Adiposity in Adipocyte-Specific Pla2g5 Transgenic Mice
To explore whether the forced overexpression of PLA2G5 in the WAT would yield outcomes opposite to its deletion, we Mice were fed a LFD or HFD for 26 weeks. Data are compiled from (A, B, and E) or representative of (C, D, and F) two experiments. Mean ± SEM; *p < 0.05, **p < 0.01. Figure S6B ). Even on a LFD, where the influence of diet-inducible endogenous PLA2G5 is negligible, Fabp4-Pla2g5 tg/+ mice had body weight significantly lower than that of age-matched control mice ( Figure S6C ). CT scanning revealed a reduced adiposity in Fabp4-Pla2g5 tg/+ mice relative to control mice ( Figure S6D ). Phospholipid levels in plasma and LDL were significantly lower in Fabp4-Pla2g5 tg/+ mice than in control mice ( Figure S6E ). Moreover, WAT expression levels of proinflammatory genes, but not lipogenic genes, tended to be lower in Pla2g5 tg/+ mice than in control mice ( Figure S6F ). After 6 weeks of HFD feeding, when the induction of endogenous Pla2g5 was still minimal ( Figure S1B ), Fabp4-Pla2g5 tg/+ mice displayed better insulin sensitivity and lower WAT expression of Ccl2 compared to control mice (Figures S6G and S6H) . Collectively, the data for adipocyte-specific PLA2G5 overexpression reciprocated those for PLA2G5 deficiency. To address the roles of PLA2G2E, we generated Pla2g2e -/-mice ( Figures S7A and S7B) . Expression of mRNA and protein for PLA2G2E was absent in WAT of HFD-fed Pla2g2e -/-mice (Figure S7C) . On a HFD, obesity and weight gain tended to be lower (though statistically insignificant) in Pla2g2e -/-mice than in Pla2g2e +/+ mice ( Figures 6A and 6B) . Volumes of total, visceral, and subcutaneous fats ( Figure 6C ) and adipocyte size in perigonadal WAT ( Figure 6D ) were significantly reduced in HFD-fed Pla2g2e -/-mice relative to Pla2g2e +/+ mice. Plasma leptin and insulin levels ( Figures S7D and S7E ), glucose and insulin tolerances ( Figures S7F and S7G ), food intake, locomotion and oxygen consumption ( Figures S7H-S7J) , and WAT expression of adipogenenic, lipogenic, lipolytic, and inflammatory genes ( Figure S7K ) did not differ between HFD-fed Pla2g2e +/+ and Pla2g2e -/-mice. HFD-induced fatty liver was mildly ameliorated by PLA2G2E deficiency, as revealed by reductions of hepatic lipid deposition ( Figures 6E and 6F ), plasma ALT, and aspartate amino transferase (AST) levels ( Figure 6G ), and hepatic expression of some genes for lipid storage and inflammation ( Figure S7L ) in HFD-fed Pla2g2e -/-mice compared to WT littermates. Lower hepatic Lpl expression in Pla2g2e -/-mice ( Figure S7L ) might partly contribute to the reduced fat uptake into the liver.
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HFD-induced increases in plasma phospholipids and cholesterol were lower in Pla2g2e
-/-mice than in Pla2g2e +/+ mice ( Figure 6H ), suggesting that PLA2G2E alters lipoprotein composition. Indeed, phospholipids, TG, and cholesterol in VLDL, LDL, and HDL were significantly lower in HFD-fed Pla2g2e -/-mice than in Pla2g2e +/+ mice ( Figures 6I and S7M ). Figure 6J ) and HDL (data not shown) in Pla2g2e -/-mice contained more PE and PS species, with no apparent fatty acid selectivity, than those in Pla2g2e +/+ mice, while PC species did not differ in both genotypes, suggesting that adipocyte-derived PLA2G2E acts on PE and PS in favor of PC in lipoproteins. The increase of these minor phospholipids by PLA2G2E deficiency may eventually decrease the relative proportion of PC and other lipids in lipoproteins, thereby affecting lipid partitioning among tissues. Taken together, PLA2G5 is protective against metabolic disorders by hydrolyzing PC in hyperlipidemic LDL to release unsaturated fatty acids, which attenuate adipose tissue inflammation through M2 macrophage skewing, while PLA2G2E mildly promotes adiposity and fatty liver by altering the proportion of PE and PS in lipoproteins (Figure 7) .
ESI-MS revealed that LDL (
DISCUSSION
Adipocyte hypertrophy results in secretion of bioactive factors such as adipokines, chemokines, and free fatty acids, which adversely affect inflammation and tissue remodeling while providing valuable protection against lipotoxic effects of excess lipid exposure (Despré s and Lemieux, 2006) . We now show that two particular sPLA 2 s are induced in hypertrophic adipocytes and play distinct roles in metabolic control in the context of diet-induced obesity. Our results add the sPLA 2 family to a growing list of extracellular lipolytic enzymes that can control systemic metabolic states and give another insight into the paracrine role of sPLA 2 in response to a given microenvironmental cue.
The obesity-driven induction of PLA2G5 in hypertrophic adipocytes, along with its constitutive expression at relatively high levels in the heart and skeletal muscle, which have a high demand for lipid as an energy source, suggests that one of the primary roles of this sPLA 2 may be related to the regulation of energy metabolism. We show here that Pla2g5 ablation exacerbates diet-induced obesity, hyperlilidemia, and insulin resistance, providing insight into the beneficial role of PLA2G5 in metabolic disorders. PLA2G5 can hydrolyze PC in lipoproteins in vitro (Sato et al., 2008) , and our present results show that this reaction does occur in vivo in the context of obesity, where adipocyte-driven PLA2G5 hydrolyzes excess PC in lipid-overladen LDL, eventually protecting from hyperlipidemia. In this regard, the metabolic effects of PLA2G5 are similar to those of lipoprotein lipase, whose expression also shows a reciprocal relationship with obesity-related traits (Chen et al., 2008) . Even though it has been thought that mice are not always good models to study LDL metabolism, as they use VLDL and HDL primarily, our results show that LDL metabolism by sPLA 2 can influence systemic metabolic states. The increased LDL-TG levels and the reduced physical activities in Pla2g5 À/À mice could impact adipocyte hypertrophy, hepatic steatosis, and WAT inflammation. Importantly, PLA2G5 expression in human WAT inversely correlates with plasma LDL levels, implying a human relevance of our observations. Moreover, our findings are also compatible with the association of PLA2G5 mutations with LDL levels in subjects with type 2 diabetes or obesity (Sergouniotis et al., 2011; Wootton et al., 2007) . Importantly, PLA2G5 plays an anti-inflammatory role in obesity, which likely makes a major contribution to the exacerbated obesity, insulin resistance, and hyperlipidemia in Pla2g5 À/À mice. This action of PLA2G5 depends on its capacity to hydrolyze phospholipids in LDL to release unsaturated fatty acids, which can allow the polarization shift of macrophages from the M1 to M2 state. Reportedly, fatty acids released from lipoproteins by venom sPLA 2 or lipoprotein lipase can facilitate anti-inflammatory responses in vitro (Ahmed et al., 2006; Duncan et al., 2010; Namgaladze et al., 2010) . Herein, we demonstrate that unsaturated fatty acids including OA > LA, which are supplied by PLA2G5-driven hydrolysis of PC in hyperlipidemic LDL, prevent PA-induced M1 macrophage polarization, likely through attenuating the ER stress, revealing a functional link between lipoprotein metabolism and anti-inflammation by this sPLA 2 . This mechanism fits with the view that PLA2G5 displays an apparent (even if not strict) substrate preference for PC bearing a fatty acid with a low degree of unsaturation. Our study provides in vivo evidence that sPLA 2 acts in this manner, thus providing a rationale for the long-standing question on the physiological importance of lipoprotein hydrolysis by this enzyme family and revealing an anti-inflammatory mechanism exerted by a particular sPLA 2 . Nonetheless, it cannot be fully ruled out that the mobilization of PGE 2 , a u6 AA-derived eicosanoid that promotes M2 macrophage skewing (Heusinkveld et al., 2011) , or u3 PUFA metabolites, which are protective against metabolic disorders (Oh and Olefsky, 2012; Spite et al., 2014) , might also partly underlie the antiobese action of PLA2G5.
As another intriguing feature of PLA2G5, we show that it is a ''Th2/M2-prone sPLA 2 '' that allows the immune balance shift toward the Th2/M2 status. Given the increased metabolic (Odegaard and Chawla, 2013) , the lack of PLA2G5 may also decrease the whole-body Th2-M2 status, thereby aggravating obesity-related inflammation. This notion agrees with the fact that Pla2g5 À/À mice are resistant to asthma (Giannattasio et al., 2010; Henderson et al., 2013) , where Th2 cells and M2 macrophages promote allergy, while they suffer from exaggerated arthritis or infection (Balestrieri et al., 2009; Boilard et al., 2010) , where Th2 immunity counteracts Th1/ Th17-based inflammation, thus accounting for the pro-versus anti-inflammatory actions of PLA2G5 in distinct immunopathological settings. As the phagocytotic activities are distinct among macrophage subsets (Leidi et al., 2009; Titos et al., 2011) , the altered M1/M2 ratio of macrophages in obese Pla2g5 -/-WAT could explain the perturbed clearance of dead cells. This idea also accords with the finding that Pla2g5 ablation decreases macrophage uptake of exogenous materials (Balestrieri et al., 2009; Boilard et al., 2010) . We also show the in vivo role of PLA2G2E as another obesityinduced, adipocyte-derived sPLA 2 . In contrast to PLA2G5 that hydrolyzes PC in LDL, PLA2G2E acts on PE and PS in VLDL, LDL, and HDL. As such, PLA2G2E alters lipid composition in lipoprotein particles, eventually moderately facilitating fat deposition in tissues. Although little is known about the role of PE or PS in lipoproteins, our study has shed light on the importance of these minor lipoprotein phospholipids in the metabolic regulation and opened an opportunity to analyze this issue using Pla2g2e À/À mice as a tool. As the increase of negative charges in lipoproteins by oxidative modification renders the particles smaller (Hidaka et al., 2005) , the increase of anionic phospholipids (e.g., PS) in lipoproteins may afford a similar effect. Lipoproteins with increased negative charges are more susceptible to hydrolysis by hepatic lipase, resulting in smaller particles (Boucher et al., 2007) . Anionic phospholipids decrease the affinity of ApoE for its receptor, thereby reducing lipid transfer into tissues (Yamamoto and Ryan, 2007) . Alternatively, Lyso-PE or Lyso-PS produced by PLA2G2E might have some metabolic effects, a possibility that needs to be addressed. Compatible with our present study, PLA2G2A in place of PLA2G2E is induced in obese rats in which the metabolic symptoms are blocked by a PLA2G2A inhibitor (Iyer et al., 2012) . In summary, our study underscores the physiological relevance of lipoprotein hydrolysis by sPLA 2 s, highlights metabolic sPLA 2 s as integrated regulators of immune and metabolic responses, and brings about a shift toward a better understanding of the biological roles of this extracellular lipolytic enzyme family as a metabolic coordinator. The contrasting metabolic effects of PLA2G5 and PLA2G2E are reminiscent of distinct roles of PLA2G5 and PLA2G2A in arthritis (Boilard et al., 2010), PLA2G5 and PLA2G10 in atherosclerosis (Ait-Oufella et al., 2013; Bostrom et al., 2007) , or PLA2G2D and PLA2G5 in antigen-presenting cells (Giannattasio et al., 2010; Miki et al., 2013) , warning about the use of pan-sPLA 2 inhibitors for therapy and pointing to an alternative strategy to use a sPLA 2 inhibitor specific for individual sPLA 2 s. Targeting the metabolic sPLA 2 s and their organ expression will be a challenge, since these enzymes appear to play highly selective roles in specific organs and disease states.
EXPERIMENTAL PROCEDURES Mice
Pla2g5
-/- (Satake et al., 2004) , Pla2g5 tg/+ (Ohtsuki et al., 2006) , and their littermate control mice were backcrossed onto the C57BL/6 mice (Japan SLC) for >12 generations. In obesity, PLA2G2E is induced in adipocytes in accordance with adipogenesis and hydrolyzes PE and PS in VLDL, LDL, and HDL, eventually promoting fat storage in WAT and liver. Subsequently, obesity-associated stress induces PLA2G5 in hypertrophic adipocytes. PLA2G5 hydrolyzes PC in hyperlipidemic LDL and facilitates the skewing of macrophages from M1 to M2 subsets, thereby playing protective roles against adipose tissue inflammation, insulin resistance, obesity, fatty liver, and hyperlipidemia. Saturated fatty acids (e.g., palmitate) supplied abundantly from adipocytes trigger M1 polarization of macrophages, which is ameliorated by PLA2G5-driven unsaturated fatty acids (oleate > linoleate) from LDL or possibly some lipid mediators from macrophages. It remains unknown whether particular PLA2G2E-produced lipid mediator(s) would participate in this process.
or LFD for appropriate periods. All procedures were performed in accordance with approvals by the Institutional Animal Care and Use Committees of Tokyo Metropolitan Institute of Medical Science, Showa University, and the University of Washington.
Quantitative RT-PCR Total RNA was extracted from tissues using TRIzol reagent (Invitrogen). Firststrand cDNA synthesis was performed using a High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems). PCR reactions were carried out using a Power SYBR Green PCR system (Applied Biosystems) or a TaqMan Gene Expression System (Applied Biosystems) on the ABI7300 Real Time PCR system (Applied Biosystems). The probe/primer sets used are listed in Tables S3 and S4 .
Microarray
Total RNA was extracted from WAT derived from female C57BL/6 mice fed a LFD or HFD for 18 weeks and purified using the RNeasy Mini Kit (QIAGEN). 
Glucose and Insulin Tolerance Tests
Mice were fasted for 16 and 6 hr before intraperitoneal injection of glucose (2 mg glucose/g body weight) (Wako) and insulin (0.75 mIU/g body weight) (Eli Lilly) in saline, respectively. Blood glucose concentrations were monitored at various time intervals using a Medisafe-Mini blood glucose monitoring system (Terumo).
Measurement of Serum Biomedical Markers
Serum insulin and leptin levels were quantified by a mouse insulin ELISA kit (Mercodia) and a leptin immunoassay kit (R&D Systems), respectively. Serum ALT and AST levels were quantified using the transaminase CII-test Wako kit (Wako).
CT Analysis
Mice were anesthetized with nembutal (0.5 mg/g body weight) (Dainippon Sumitomo Pharma), and their adiposity was analyzed using the micro-CT systems eXplore Lucus Micro CT Scanner (GE Healthcare) or Latheta LCT-100 (Aloka).
Oxygen Consumption and Locomotor Activity
Oxygen consumption was measured every 3 min over 24 hr under resting conditions using an MK-5000RQ metabolism measuring system for small animals (Muromachi Kikai). For measurement of basal locomotor activity, mice were placed into chambers of an ACTIMO-S food intake, drinking, and locomotor activity monitoring system (Shintechno). Food and water were provided ad libitum. Mice were allowed to acclimatize in the chambers for 24 hr, and then their physical activities were measured over the next 24 hr.
Analyses of Plasma Lipids and Lipoproteins
Analysis of plasma lipoproteins was performed by LipoSearch (Skylight Biotech). Plasma cholesterol, phospholipid, LPC, TG, and NEFA levels were determined with a Determinar TC2 (Kyowa Medex), a Phospholipid C Test (Wako), a LPC Assay kit (AZWELL), a Determinar TG2 (Kyowa Medex), and a NEFA C Kit (Wako), respectively.
ESI-MS/MS
Lipid analysis was performed using a 4000 QTRAP quadrupole-linear ion trap hybrid MS (AB SCIEX) with liquid chromatography (LC-20AP; Shimazu) combined with a HTS PAL autosampler (CTC Analytics AG), as detailed in Supplemental Information.
Cell Culture Studies Studies using adipocytes and immune cells are detailed in Supplemental Information.
Human Samples
Mesenteric WAT and fatty appendices were obtained by curative resection from 64 patients with colorectal tumors, all of whom underwent elective surgical colorectomy at the Kumamoto University Hospital (Kumamoto, Japan) from March 1, 2012 to August 31, 2013. The clinical characteristics are summarized in Table S2 . The study was approved by the Ethics Committees of Kumamoto University, with written informed consent from all patients.
Statistical Analyses
All values are given as the mean ± SEM. Differences between two groups were assessed by using the unpaired two-tailed t test. Data involving more than two groups were assessed by ANOVA, and relationships between clinical and metabolic parameters were assessed by Spearman's rank correlation test. Correlation coefficients (R) and probability (P) values were calculated with the Excel Statistical Program File yStat 2008 (Igaku Tosho Shuppan).
ACCESSION NUMBERS
The GEO accession number for microarray data reported in this paper is GSE56038.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, seven figures, and four tables and can be found with this article online at http://dx.doi.org/10.1016/j.cmet.2014.05.002.
